Quarterly ResultJul 20, 2026, 07:33 PM
Telix Q2 Revenue $247M, FY26 Guidance Exceeds $1B
AI Summary
Telix Pharmaceuticals reported strong Q2 2026 results with group revenue reaching $247 million, a 21% increase year-over-year. Precision Medicine revenue grew 30% YoY to $202 million. The company expects FY 2026 revenue and other income to exceed $1 billion, aligning with the upper end of its guidance. Key operational milestones include FDA alignment for the ProstACT Global Phase 3 study, nearing completion of patient enrollment for the BiPASS™ study, and the FDA's acceptance of the Pixclara® NDA with a September PDUFA date. Telix also announced a strategic collaboration with Regeneron, including a $40 million payment, and updated its FY 2026 R&D expenditure guidance to $230 million to $270 million.
Key Highlights
- Group revenue for Q2 2026 was $247 million, up 7% QoQ and 21% YoY.
- Precision Medicine revenue was $202 million, up 9% QoQ and 30% YoY.
- Telix expects FY 2026 revenue and other income to exceed $1 billion, tracking the upper end of guidance.
- Strategic collaboration with Regeneron includes a $40 million non-refundable payment.
- FY 2026 R&D expenditure guidance updated to $230 million to $270 million.
- FDA aligned on ProstACT Global Phase 3 study for TLX591-Tx to advance to Part 2 in the U.S.
- Patient enrollment nearing completion for BiPASS™ study of Illuccix® and Gozellix®.
- FDA accepted resubmitted NDA for Pixclara® with a PDUFA goal date of September 11, 2026.
Price Impact
More from TLX